Loading organizations...
Key people at Nature Immunology.
Nature Immunology operates as a premier multidisciplinary journal, dedicated to publishing papers of exceptional quality and significance across all domains of immunology. It focuses on research that yields both fundamental and translational insights into the intricate functions of the immune system. Beyond original research, the publication curates comments, news, research highlights, and literature reviews, employing a rigorous and rapid peer-review process to ensure scientific integrity and timely dissemination.
The journal was established in 2000, launched by the Nature Publishing Group, now part of Springer Nature. This initiative stemmed from a recognized need to provide a dedicated, high-impact platform within the esteemed Nature portfolio for the rapidly evolving field of immunology. The inception aimed to centralize and elevate the discourse around immunological discoveries, offering a trusted venue for ground-breaking studies.
Nature Immunology primarily serves a global audience of immunologists, researchers, and scientific institutions seeking leading-edge discoveries. Its overarching vision is to act as a vital conduit for top-tier information, actively shaping and propelling the advancement of immunological science. Through its publications, it endeavors to facilitate deeper understanding and inspire future innovations in the field.
Key people at Nature Immunology.
I need to clarify an important distinction: Nature Immunology is not a company—it is a peer-reviewed scientific journal published by Nature Portfolio (part of Springer Nature). The premise of your query contains an inaccuracy that prevents me from providing the analysis you've requested.
Nature Immunology is a multidisciplinary academic journal that publishes high-quality research across all areas of immunology.[1] It ranks third among 128 journals in the immunology field and first among primary research journals in immunology, with a 2009 impact factor of 26.000.[4] The journal covers diverse topics including cancer immunology, infectious disease immunology, DNA-sensing pathways, stromal-immune cell interactions, and vaccine development strategies.[1][2]
As a Nature Portfolio publication, it operates under the editorial and publishing infrastructure of Springer Nature, with principal offices in London, New York, Berlin, Shanghai, and Tokyo.[3] The journal publishes articles under Creative Commons licenses, including CC BY-NC-ND and CC BY options for open access content.[6]
If you intended to ask about ImmunityBio—a clinical-stage biotechnology company focused on immunotherapies—that would be a different subject entirely. ImmunityBio was founded in 2014 by Dr. Patrick Soon-Shiong and develops novel treatments for advanced cancers and infectious diseases using natural killer cell platforms and antibody cytokine fusion proteins.[1]
Please clarify whether you'd like analysis of ImmunityBio as an investment opportunity, or if you have other questions about Nature Immunology as a scientific publication.
